trending Market Intelligence /marketintelligence/en/news-insights/trending/nt7TpCIaP5LF8B0FAR1AVw2 content esgSubNav
Log in to other products

Login to Market Intelligence Platform


Looking for more?

Contact Us
In This List

ImmunoGen closes $108.4M common stock offering

COVID-19 Pandemic Likely To Cause US Telemedicine Boom

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry


IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

ImmunoGen closes $108.4M common stock offering

ImmunoGen Inc. closed its underwritten public offering of 16,675,000 common shares priced at $6.50 apiece for gross proceeds of $108.4 million.

The shares sold included 2,175,000 shares sold pursuant to the underwriters' full exercise of their option to buy additional shares.

ImmunoGen plans to use the net proceeds, together with its existing capital, to fund its operations, including, but not limited to, research and development activities, clinical trial activities, manufacturing and supply of drug substance and drug products, commercialization preparation, acquisitions of new technologies, capital expenditures and working capital.

Jefferies, Leerink Partners and RBC Capital Markets acted as joint book-running managers and Canaccord Genuity acted as sole co-manager for the offering.